Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

since several batches of product that were manufactured during the latter part of the second quarter were not shipped until the third quarter, when these revenues will be recorded.

Total costs and expenses decreased $1,954,000 to $6,491,000 in the second quarter of FY 2009 from $8,445,000 in the same prior year quarter, a decrease of 23%. The decrease was primarily related to planned reductions in R&D costs associated with Peregrine's preclinical programs. These reductions were implemented to maximize the R&D resources available to advance the company's priority clinical product candidates bavituximab and Cotara(R). R&D expenses were $4,301,000 in the second quarter of FY 2009, compared to $5,100,000 in the second quarter of FY 2008. The decrease in R&D expense was achieved despite an increase in clinical activity during the quarter. SG&A expenses were down $416,000 to $1,527,000 for the second quarter of FY 2009 compared to $1,943,000 for the comparable period in FY 2008, a decrease of 21%. This decrease reflects a reduction in SG&A expenses across the board, reflecting the company's focus on stringent management of all discretionary expense categories.

At October 31, 2008, the company had $8,210,000 in cash and cash equivalents. After the close of the quarter, on December 9, 2008, Peregrine entered into an agreement for a non-convertible term loan with an initial tranche of $5 million that will be funded upon closing, with an option to acquire a second $5 million tranche in the future, upon Peregrine's satisfaction of certain additional conditions.

"This past quarter was highlighted by significant milestones for both our bavituximab cancer and anti-viral programs," said Steven W. King, president and CEO of Peregrine. "For the first time, we reported patient enrollment underway in three bavituximab Phase II cancer trials, along with encouraging updated results from o
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... accurate method of assessing people at risk from cardiovascular disease ... those at risk among black and minority ethnic groups. ... most at risk of developing CVD for the first time, ... and other clinical conditions such as family history of heart ...
... 24 The Rehabilitation Institute,of Chicago and MediCom ... on Pain July 18th and 19th. The meeting ... of Northwestern University in Chicago., This year, ... Opioid,Management." The scientific agenda will focus on the ...
... Food Snacks Contain Ingredients Medically Proven to Reduce ... Impact of Diagnosed ... In response to increasing,demand for convenient, tasty, satisfying foods ... WatchDog Nutrition(TM) today announced,availability of its snack bars in ...
... BETHLEHEM, Pa., June 24 At this year,s ... Inc. and its MIKE AND,IKE(R) Candy Brand presented ... the first in a multi-year commitment to this ... MIKE AND IKE(R) Lemonade Blends(TM) kicks off Just ...
... June 24 Go Healthy, Inc. (Pink,Sheets: GOHE) announced ... AIM Marketing, based in Myakka, Florida. Under the terms ... number of marketing and,sales related services designed to bring ... clients. Some specifics outlined in the agreement,are as follows:, ...
... June 24 /PRNewswire-FirstCall/ - Beeston Enterprises Ltd.,("Beeston" or ... on its Bluff Lake property that it holds ... "CDO"). The property is,located on the northern border ... continues to delineate significant alkalic copper-gold deposits., ...
Cached Medicine News:Health News:New cardiovascular score developed to improve heart attack and stroke detection 2Health News:3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc. 2Health News:Heart Disease and Diabetes Finally Meet Their Match With Delicious New Snack Bars From WatchDog Nutrition(TM) 2Health News:MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alex's Lemonade Stand Foundation 2Health News:Go Healthy Signs Marketing Contract with AIM Marketing 2Health News:Beeston completes drilling on Bluff Lake property, 100 Mile House 2
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
(Date:12/15/2014)... Washington State are not the only ... Oregon , Alaska , and ... 2014 elections. Photo - http://photos.prnewswire.com/prnh/20141212/164152 ... The benefits of legalizing cannabis are manifold. There are the ... revenue for state and local governments, in addition to reduced ...
(Date:12/15/2014)... SAN MARCOS, Texas , Dec. 15, 2014 /PRNewswire/ ... quantum dot manufacturer Quantum Materials Corp (OTCQB:QTMM), ... Rice Center for Quantum Materials (RCQM) on December 16th, ... the exploration of exotic nanomaterials in attracting top faculty ... to Rice to collaborate on research. ...
Breaking Medicine Technology:Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
... Agennix Incorporated today announced,the publication of final ... alfa in patients who had failed previous treatment ... from the study,which were reported in the July ... 1), demonstrate that talactoferrin is active in RCC, ...
... Evaluate Preventive Treatment of ... Vulnerable Plaques, ROTTERDAM, Netherlands and DOYLESTOWN, Pa., June ... W. Serruys,successfully placed a vProtect(TM) Luminal Shield in the ... at Erasmus Medical,Center in Rotterdam. This case marks the ...
Cached Medicine Technology:Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 2Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 3Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 4Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 5Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 2Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 3
A straight suture punch with 2.5 mm needle and 2/0 to #1 monofilament suture....
Leg holder for arthroscopy....
... High-Performance Pump in Arthroscopy. Ease of use ... that make the 10k Fluid System unique. ... for Arthroscopy, maintains intra-articular pressure, while providing ... Fluid System, when used for Laparoscopy, provides ...
The Sony DSR20-MD Grade Digital Video Player/Recorder represents a giant leap in digital technology. , ,This equipment is intended to be used by physicians who teach or present medical techniques...
Medicine Products: